The Anticonvulsants are the diverse group of the pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder. They seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the rapid and excessive firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.
Anticonvulsant drugs are primarily developed for the treatment of epilepsy, a neurological condition that affects around the 50 million people worldwide. They reduce seizure frequency by suppressing neuronal excitability via various molecular targets in the synapse, including voltage-gated ion channels, voltage-gated GABAA (γ-aminobutyric acid type A) receptors and glutamate receptors.

The global Anticonvulsants market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Anticonvulsants volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anticonvulsants market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Anticonvulsants in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Anticonvulsants manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Johnson & Johnson (J&J)
Novartis AG
UCB Group
GlaxoSmithKline plc.
Pfizer Inc.
Abbott Laboratories
Cephalon Inc.
Shire plc.

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Epilepsy
Fibromyalgia
Migraine
Neuropathic pain
Bipolar disorder
Anxiety
Borderline personality disorder

Segment by Application
Hospital
Clinic
Home Care